Natera Validates Tissue-Free MRD Test in Colorectal Cancer
Austin, Texas, January 21, 2026 — Natera, a global leader in cell-free DNA and precision medicine, announced the peer-reviewed...
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
Austin, Texas, January 21, 2026 — Natera, a global leader in cell-free DNA and precision medicine, announced the peer-reviewed...
AUSTIN, Texas — December 5, 2025 — Natera has announced the acquisition of Foresight Diagnostics, a precision oncology company...
